Chordia Therapeutics Inc. (JP:190A)
:190A
Want to see JP:190A full AI Analyst Report?
190A Stock Chart & Stats
¥108.00
-¥9.00(-2.81%)
At close: 4:00 PM EST
¥108.00
-¥9.00(-2.81%)
Day’s Range― - ―
52-Week Range¥98.00 - ¥241.00
Previous CloseN/A
Volume2.20M
Average Volume (3M)565.44K
Market Cap
¥8.94B
Enterprise Value¥6.35B
Total Cash (Recent Filing)¥2.55B
Total Debt (Recent Filing)¥0.00
Price to Earnings (P/E)―
Beta0.68
Next Earnings
Jul 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-26.05
Shares Outstanding76,392,400
10 Day Avg. Volume542,310
30 Day Avg. Volume565,443
Financial Highlights & Ratios
PEG Ratio0.42
Price to Book (P/B)5.07
Price to Sales (P/S)0.00
P/FCF Ratio-6.70
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageNo reported debt materially reduces fixed financing obligations and solvency risk, giving management flexibility to fund oncology R&D through equity, partnerships or milestone deals. This durable advantage preserves optionality across multi-year clinical cycles and reduces bankruptcy risk.
Proven Revenue/profitability HistoryHaving produced revenue and profits in 2023 shows the company can commercialize or monetize assets, reducing binary risk versus firms with no track record. This prior operational success supports credibility with partners and indicates underlying capabilities that can be redeployed to rebuild sustainable revenue over months to years.
Focused Oncology R&D PipelineA clear strategic focus on oncology small-molecule discovery aligns with large, persistent market demand and established pathways for partnerships and licensing. This structural industry alignment supports long-term value creation if clinical progress or collaborations materialize, and concentrates resource allocation.
Bears Say
Zero Recent Revenue And Large LossesA shift back to zero revenue and steep net losses undermines margin sustainability and raises structural questions about commercial continuity. Over multiple quarters this erodes operating leverage, increases reliance on external funding, and weakens the firm's ability to self-fund clinical development without dilutive financing or strategic transactions.
Sustained Cash BurnPersistent large negative operating cash flow rapidly consumes liquidity and shortens runway, forcing recurring capital raises or partnership transactions. For a biotech, sustained cash burn elevates execution risk for multi-year clinical programs and increases probability of dilutive financing that can impair long-term shareholder returns.
Eroding Equity BaseA materially shrinking equity base signals capital erosion from repeated losses, reducing the balance-sheet buffer against shocks. Lower equity constrains financing flexibility, raises borrowing or raising-equity costs, and weakens the company’s capacity to absorb further clinical setbacks without materially altering strategic options.
Chordia Therapeutics Inc. News
190A FAQ
What was Chordia Therapeutics Inc.’s price range in the past 12 months?
Chordia Therapeutics Inc. lowest stock price was ¥98.00 and its highest was ¥241.00 in the past 12 months.
What is Chordia Therapeutics Inc.’s market cap?
Chordia Therapeutics Inc.’s market cap is ¥8.94B.
When is Chordia Therapeutics Inc.’s upcoming earnings report date?
Chordia Therapeutics Inc.’s upcoming earnings report date is Jul 20, 2026 which is in 63 days.
How were Chordia Therapeutics Inc.’s earnings last quarter?
Chordia Therapeutics Inc. released its earnings results on Apr 10, 2026. The company reported -¥4.71 earnings per share for the quarter, missing the consensus estimate of N/A by -¥4.71.
Is Chordia Therapeutics Inc. overvalued?
According to Wall Street analysts Chordia Therapeutics Inc.’s price is currently Overvalued.
Does Chordia Therapeutics Inc. pay dividends?
Chordia Therapeutics Inc. does not currently pay dividends.
What is Chordia Therapeutics Inc.’s EPS estimate?
Chordia Therapeutics Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Chordia Therapeutics Inc. have?
Chordia Therapeutics Inc. has 76,392,400 shares outstanding.
What happened to Chordia Therapeutics Inc.’s price movement after its last earnings report?
Chordia Therapeutics Inc. reported an EPS of -¥4.71 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.775%.
Which hedge fund is a major shareholder of Chordia Therapeutics Inc.?
Currently, no hedge funds are holding shares in JP:190A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Chordia Therapeutics Inc.
Chordia is focused on the oncology area, with its target areas ranging from exploratory research to Proof of Concept (POC). For subsequent business development, we will build a system that allows us to make the best choices for maximizing corporate value, such as out-licensing and joint development and sales.
Technical Analysis
Pharmarise Holdings Corp.
―
COSMOS Pharmaceutical Corporation
―
Tsubota Laboratory Incorporated
―
Shinnihonseiyaku Co., Ltd.
―
Heartseed, Inc.
―